A study of CCX-140 in patients with focal segmental glomerulosclerosis (FSGS)

Trial Profile

A study of CCX-140 in patients with focal segmental glomerulosclerosis (FSGS)

Planning
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs CCX 140 (Primary)
  • Indications Focal segmental glomerulosclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 07 Nov 2017 According to a ChemoCentryx media release, the company expects to initiate this train in the fourth quarter of 2017.
    • 08 Aug 2017 According to a ChemoCentryx media release, the company expects to initiate this train in later 2017.
    • 20 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top